Tumor ablation devices market seen reaching $1.61 billion by 2030

The tumor ablation therapy devices market is forecast to grow from $0.95 billion in 2026 to $1.61 billion by 2030, driven by rising cancer cases, outpatient care demand and more image-guided procedures. North America held the largest share in 2025, while Asia-Pacific ranked second.

Why it matters: - Tumor ablation therapy devices are gaining traction because they offer a minimally invasive way to destroy tumors while sparing surrounding tissue. - The market’s growth reflects broader demand for cancer treatments that reduce recovery time and preserve organs. - Rising cancer incidence is expanding the need for alternatives when chemotherapy or radiotherapy do not work.

What happened: - The Business Research Company released a report on the global tumor ablation therapy devices market with a 2026 market outlook and a forecast through 2035. - The market is projected to rise from $0.82 billion in 2025 to $0.95 billion in 2026, a 15.0% CAGR. - The same market is forecast to reach $1.61 billion by 2030, implying a 14.2% CAGR. - Download a free sample of the report. - View the full market report.

The details: - Tumor ablation therapy devices are used primarily for tumors in the kidney, liver and lung. - The devices work by targeting and destroying cancer cells while limiting damage to healthy tissue. - Reported growth drivers include rising cancer incidence, more oncology treatment centers, broader adoption of minimally invasive therapies, better access to advanced imaging and stronger preference for organ-preserving care. - Future growth is tied to investments in precision oncology, demand for outpatient cancer treatment, ablation technology improvements, tighter imaging integration and personalized cancer care. - Key trends include wider use of minimally invasive ablation procedures, greater reliance on image-guided ablation, more organ-specific ablation technologies, expanded percutaneous treatment methods and more precision oncology use. - The report says cancer is the second leading cause of death globally and accounts for about one in six deaths. - Aging populations are increasing lifetime cancer risk and adding to treatment demand. - The American Cancer Society projected 1,958,310 new cancer diagnoses in the U.S. in 2023, up from 1,918,030 in 2022. - Tumor ablation is also used for tumors in the bone. - Tumor ablation can be especially valuable for patients who do not respond to chemotherapy or radiotherapy.

Between the lines: - The forecast points to a market moving from niche procedural use toward broader oncology workflows. - Imaging integration appears to be a central competitive advantage, since the report ties future demand to more precise, image-guided treatment. - The outpatient care trend suggests hospitals and cancer centers may keep shifting some treatment volume away from more invasive procedures. - North America’s lead in 2025 suggests the region has the deepest current adoption, while Asia-Pacific may offer the most room for expansion.

What's next: - The report expects continued growth through 2030 as precision oncology and minimally invasive treatment adoption accelerate. - North America remains the largest regional market, with Asia-Pacific in second place and positioned for further growth. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - Expanded report features include market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspots infographics and updated graphics and tables.

The bottom line: - Tumor ablation devices are on track for steady double-digit growth as cancer care shifts toward less invasive, image-guided and more personalized treatment.